Revenue
Margin
Demand
Guidance
Tone
Metrics raised 2
- FY27–FY29 EBITDA margin target (Expand phase) raised/stepped up to 11–13% (from ~9–11% current/Strengthen phase)
- FY30+ EBITDA margin target (Transform phase) raised to 13–18% (from ~11–13% Expand phase)
Event Participants
Executives
3 Krishna Bodanapu, R.M. Subramanian, Rajendra Velagapudi
Analysts
11 Adityapal, Anil Mehta, Balasubramanian, Deepak, Deepak Krishnan, Gaurav Shukla, Praveen Sahay, Sameet Sinha, Santhosh Seshadri, Shubhi Gupta, Vipraw Srivastava
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Order Book | ₹2,598 crores | Highest ever in company history; +₹183.2 crores QoQ; provides strong revenue visibility for coming quarters |
| Order Intake | ₹551.9 crores | Book-to-bill of 1.5x; driven by existing customers deepening engagement and new customers coming on board |
| Revenue | ₹373.8 crores | +34.3% YoY (from ₹278.4 crores); strongest Q1 ever; supported by healthy order book, improved execution momentum and continued demand |
| EBITDA | ₹39.2 crores | +56.2% YoY (from ₹25.1 crores); fourth consecutive quarter of double-digit EBITDA margin |
| EBITDA Margin | 10.5% | +147 bps YoY from 9.0%; driven by operating leverage, better revenue mix and disciplined cost management |
| PBT | ₹22.2 crores | More than doubled YoY; aided by 29% YoY reduction in finance costs on lower working capital borrowings |
| PAT | ₹16.3 crores | +118.2% YoY (from ₹7.5 crores); PAT margin expanded 168 bps YoY to 4.4% |
| Inventory Days (DIO) | 162 days | vs 153 days in Q4 FY26; elevated due to strategic inventory build-up of critical components to de-risk supply chain amid geopolitical disruptions |
| Net Working Capital Days | 161 days | vs 145 days in Q4 FY26; increase driven by inventory build-up and moderation in customer advances (15 days vs 18 days) |
| Days Sales Outstanding | 77 days | Broadly stable vs 74 days in Q4 FY26; disciplined collections despite higher business volumes |
| Days Payable Outstanding | 63 days | Reduced over recent quarters; reflects normalization of supplier payment cycles and stronger supplier relationships |
Geographic & Segment Commentary
- Aerospace: 42% of Q1 FY27 revenue, +40% YoY. Honeywell initial builds are underway with ramp-up expected over the next 18 months; Thales engagement expected to deliver "extraordinary growth" this year. Management characterizes aerospace as a "moat" — very difficult to enter, but once established, it provides a steady revenue stream.
- Industrial: 32% of revenue, +90% YoY. Strongest growth segment in the quarter; two new logos added during the quarter across industrial and automotive segments.
- Defence: 9% of revenue, +35% YoY. Order intake momentum from Israeli customers continuing in Q2 and beyond; strong build-to-print momentum in North America and Europe; early-stage build-to-spec work with a European defence organization.
- MedTech: 16% of revenue, flat YoY. Growth impacted by seasonality at one customer; MedTech represents ~17–20% of the sales pipeline; management expressed no concern for the rest of the year.
- Auto & Others: 1% of revenue.
- Product Category Mix: PCBA 48% of revenue (+21% YoY); Box build 21% (+85% YoY); Mechanical & others 10%; Cables 1%; other categories including B2S.
- Geographic Mix: Rest of world 94%, India 6%; higher ROW share driven by aerospace, medical, defence and industrial customers outside India.
Company-Specific & Strategic Commentary
- SET Strategy Roadmap: Three-phase progression — Strengthen (current: aerospace, defence, medical, industrial, automotive/EV; EBITDA margins ~9–11%), Expand (FY27–FY29: same stack into robotics and AI/data centre; margins step up to ~11–13%), Transform (FY30+: B2S products and platforms with IP ownership; margins ~13–18%).
- Market Opportunity: Global EMS market currently
$625–650 billion, expected to approach ~$1.1 trillion by 2033 (6%+ blended CAGR); company deliberately positions in high-reliability, high-value segments rather than commodity high-volume work. - B2S Capability Expansion: Build-to-spec lab expanded from 6,000 to 15,000 sq ft (more than doubled); strong order pipeline from key customers; Nadcap certification completed for cable harness assembly at Mysore unit, reinforcing aerospace-grade credibility.
- Leadership & Go-to-Market: Key leadership hiring mostly completed; Rama Alapati appointed Chief Strategy and Growth Officer; sales directors onboarded for AI/data centre push.
- Order Pipeline Composition: ~48% aerospace & defence, ~40% industrial and semiconductor capital equipment, balance from medical and automotive.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Book-to-Bill | ~1.5x for FY27 | Management explicitly guided to maintaining 1.5x book-to-bill ratio for the full year |
| Revenue Momentum | Similar range in Q2 and beyond | No major concern on revenue or order intake momentum; West Asia disruptions already planned for in Q2 |
| B2S Revenue Contribution | Substantial revenues in next 1–2 years | B2S opportunities expected to add 250–300 bps to consolidated EBITDA margin |
| Semiconductor Capital Equipment | Revenue growth over next 6–12 months | Continued work with semicon capital equipment customers; expected to provide margin leverage |
| EBITDA Margin Trajectory | 11–13% (FY27–FY29); 13–18% (FY30+) | Expand phase adds robotics and AI/data centre; Transform phase layers in B2S products and platform ownership |
| Capex | No incremental capex beyond regular annual | Current capacity ~1.75x–2x of revenue; existing manufacturing footprint sufficient for new segments |
Risks & Constraints
| Risk | Context |
|---|---|
| West Asia Geopolitical Disruptions | Ongoing crisis causing logistics/shipment delays and rising costs; management mitigated impact via strategic inventory build-up and proactive planning, with Q2 plans already in place; Israeli customer order intake momentum continues |
| Working Capital & Cash Flow Pressure | Net working capital days rose to 161 (vs 145 in Q4 FY26) with inventory at 162 days; negative free cash flow driven by growth-related inventory build-up and lower customer advances; management expects cash flow to turn positive once growth establishes and inventory comes under control |
| MedTech Concentration / Seasonality | MedTech revenue flat YoY due to seasonal impact from one customer; pipeline (~17–20% of sales pipeline) provides comfort, but near-term segment growth depends on customer ramp |
| Forex Exposure | Rupee appreciation in the last month of Q1 caused net adverse balance sheet impact given large export and import exposure; management acknowledged impact but provided no hedging details |
| New Segment Execution Risk | AI data centre and robotics contributions are early-stage with no disclosed order intake or revenue guidance; management expects to provide updates in 2–3 quarters; semiconductor equipment growth guided over 6–12 months |
Q&A Highlights
West Asia Crisis and Israel Orders
- Question: What is the effect of the West Asia crisis, and have the pending Israeli orders/approvals that were delayed last year progressed? (Gaurav Shukla)
- Answer: The crisis is still ongoing with logistics delays and rising costs, but proactive inventory build-up prevented Q1 impact and plans are in place for Q2. Order intake from Israeli customers has gained momentum and is expected to continue in Q2 and beyond. (Rajendra Velagapudi)
AI/Data Centre and Robotics Entry
- Question: Are there any hyperscaler discussions, and when will the AI data centre entry materialize? (Vipraw Srivastava)
- Answer: The initiative has just started; sales directors were onboarded in Q1, and updates on focus areas and momentum are expected in the next 1–2 quarters. (Rajendra Velagapudi)
- Question: What product categories are targeted within AI data centres (rack/cooling/power supply), and how much incremental capex is required? (Anil Mehta)
- Answer: Strategy and team are in place; specific product lines to be disclosed in the next 2–3 quarters. No additional capex needed — existing capacity (~1.75x–2x revenue) is sufficient. (Rajendra Velagapudi)
SET Strategy, Margin Bridge and B2S Contribution
- Question: What is the growth CAGR for FY26–FY29, the contribution from AI/robotics by FY29, and the B2S revenue/margin delta for the transform phase? (Deepak Krishnan)
- Answer: Robotics and AI focus is for FY28–FY29, with order intake expected this year; B2S internal plans underpin the margin bridge to 13–18% by FY30+. Company is not disclosing segment-level revenue guidance. (Rajendra Velagapudi)
- Question: When will B2S contribute meaningful revenue, and at what margin compared to EMS? (Praveen Sahay)
- Answer: Substantial B2S revenues expected in the next 1–2 years; B2S opportunities add 250–300 bps to consolidated EBITDA margin. (R.M. Subramanian)
Order Inflow Composition & Sustainability
- Question: Is the ₹551.9 crores order inflow sustainable, were there any lumpy one-off orders, and how much came from new logos? (Deepak, Unifi Capital)
- Answer: No lumpy orders — inflow came from both existing and new customers. ~70% from existing customers and 30% from new customers added over the last 4–6 quarters; book-to-bill guided at 1.5x for the year. (Rajendra Velagapudi)
Working Capital and Cash Flow
- Question: Operating cash flow is negative — what is the primary reason and when will working capital normalize? (Praveen Sahay)
- Answer: Negative free cash flow is driven by higher inventory and lower customer advances; inventory is a leading indicator needed to support growth and de-risk supply chains. Cash flow will turn positive once growth stabilizes and inventory comes under control. (Rajendra Velagapudi)
MedTech Flat Growth
- Question: Why is MedTech growth flat and how will it progress for the rest of the year? (Shubhi Gupta)
- Answer: Seasonal impact from one customer; the pipeline is healthy, with MedTech at ~17–20% of the sales pipeline, so there is no concern for the year. (Rajendra Velagapudi)
Aerospace Moat and European Defence Outlook
- Question: How has aerospace grown 4x on a quarterly run rate over three years, and how is the company placed for India-based outsourcing from Honeywell, Safran and Thales? (Adityapal)
- Answer: Honeywell initial builds are ramping over the next 18 months; Thales is expected to deliver extraordinary growth this year. Aerospace is a deliberate strategic moat — very difficult for new entrants to penetrate, and once inside, it provides a steady revenue stream on which other businesses can be built. (Rajendra Velagapudi, R.M. Subramanian)
- Question: With SkyDrive (Japan eVTOL) receiving certifications faster, can B2S revenue fructify sooner? What about European defence demand? (Adityapal)
- Answer: SkyDrive engineering designs are ongoing, with production likely in 1–1.5 years; B2S relationships are lifecycle-long. European defence includes an early-stage B2S engagement with one organization; build-to-print momentum remains strong in both North America and Europe. (Rajendra Velagapudi)
Margin Drivers and Sequential Gross Margin Decline
- Question: Any full-year revenue guidance, and why did gross profit/margin decline sequentially despite higher revenue? (Sameet Sinha)
- Answer: Similar revenue and order intake momentum expected in Q2 and beyond. Gross margin dip is due to budgeted organizational investments. Current margin expansion comes from filling the hopper and operating leverage; new segments will add incrementally in the future. (Rajendra Velagapudi, R.M. Subramanian)
Forex Impact
- Question: Given the company is a net exporter, what drove the forex loss in the quarter? (Deepak Krishnan)
- Answer: The rupee appreciated in the last month of the quarter; with large export and import exposure, the net impact is reflected on the balance sheet. (R.M. Subramanian)
Order Pipeline Breakup by Vertical
- Question: What is the breakup of the order pipeline by vertical (aerospace, defence, industrial, MedTech, Lane 1/Lane 2)? (Balasubramanian)
- Answer: The pipeline is substantially higher than the reported order book; ~48% aerospace & defence, ~40% industrial and semiconductor capital equipment, with the balance from medical and automotive. (Rajendra Velagapudi)
Key Takeaway
Cyient DLM delivered its strongest Q1 ever in Q1 FY27, with revenue of ₹373.8 crores (+34.3% YoY), EBITDA of ₹39.2 crores at a 10.5% margin (+147 bps YoY), marking the fourth consecutive quarter of double-digit EBITDA margins, and PAT of ₹16.3 crores (+118.2% YoY). Growth was led by industrial (+90%), aerospace (+40%) and defence (+35%), with MedTech flat on seasonality. A record order book of ₹2,598 crores (+₹183.2 crores QoQ) and 1.5x book-to-bill provide strong revenue visibility, with management guiding to 1.5x for the full year. Strategy centers on the SET roadmap: Strengthen current four industries at 9–11% margins, Expand into robotics and AI/data centre through FY27–FY29 at 11–13% margins, and Transform via B2S products/platforms at 13–18% margins by FY30+, with B2S expected to add 250–300 bps to consolidated EBITDA. The B2S lab was doubled to 15,000 sq ft and two new logos were added. Watch items include elevated net working capital (161 days) and negative free cash flow from strategic inventory build-up, ongoing West Asia logistics disruptions, and early-stage execution in AI/robotics and semiconductor capital equipment, with management confident in sustained profitable growth supported by record backlog and a strengthened leadership team.